Authoritative news and market intelligence on Health.
Eli Lilly posted significant revenue gains driven by unprecedented global demand for its blockbuster treatments Mounjaro and Zepbound, solidifying its leadership in the metabolic therapeutics market.
Merck posted robust top-line gains driven by enduring demand for blockbuster oncology drug Keytruda and rapid market adoption of newly launched Winrevair.
Moderna Chief Executive Stéphane Bancel remains steadfast on the company's individualized cancer vaccine program despite recent equity selloffs and shifting market expectations.
Sandoz shares slipped following a conservative sales forecast, prompting fresh questions about pricing power and volume growth in the generic drug sector.
Sweeping federal transparency mandates will force pharmacy benefit managers to disclose complex fee structures, reshaping revenue models across the healthcare sector.
AstraZeneca is advancing a portfolio of targeted cancer therapies to protect oncology margins and achieve its ambitious 2030 revenue targets.
Swiss pharmaceutical powerhouse Roche is ramping up its oncology pipeline, targeting critical gaps in lung cancer care across key emerging markets.
Shares of Genmab surged following encouraging clinical data from its oncology program, lifting sentiment across the European and U.S. biotechnology sectors.
Moderna shareholders face prolonged market turbulence as the biotech pioneer balances falling COVID-19 vaccine revenues with heavy R&D bets across oncology and rare diseases.